The present invention relates to the neurotoxicity that can occur as a side effect of the treatment of cancer patients with redirected T-cell therapies, such as chimeric antigen receptor (CAR) T cell therapies. The present invention provides various methods and compositions useful for treating and/or preventing such neurotoxicity, and/or for determining whether a subject is likely to develop such neurotoxicity, as well as a variety of other methods and compositions relating to the neurotoxicity associated with redirected T-cell therapies.

The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

The present invention relates to the treatment of an arthritic disease such as rheumatoid arthritis with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

Genetically engineered immune cells, which express at least two metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered immune cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The invention provides a recombinant Yarrowia lipolytica. The recombinant Yarrowia lipolytica comprises a heterologous polynucleotide encoding a fusion protein. The fusion protein comprises a first amino acid sequence and a second amino acid sequence. The first amino acid may be homologous to the amino acid sequence of 3-ketoacyl CoA thiolase (3KAT), The second amino acid sequence may be homologous to the amino acid sequence of a fatty acyl-CoA reductase (FAR). Also provided is a method for producing one or more fatty alcohols by the recombinant Yarrowia lipolytica and a method for preparing the recombinant Yarrowia lipolytica.